Skin Aging Clinical Trial
Official title:
Novel Antiaging Regenerative Skin Care Regimen Containing Human Platelet Extract (HPE)
Verified date | August 2022 |
Source | Mayo Clinic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The Researchers are trying to study a cosmetic skin care product called human platelet extract (HPE) to see if it can be used as a possible treatment for skin anti-aging and skin rejuvenation. They are trying find out the safety and tolerability of topical HPE after multiple doses of topical administration
Status | Completed |
Enrollment | 77 |
Est. completion date | July 7, 2022 |
Est. primary completion date | July 7, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 85 Years |
Eligibility | Inclusion Criteria: - Persons of childbearing potential must have a negative pregnancy test prior to receiving the study product and will agree to use adequate contraception (hormonal or barrier method or abstinence) from the time of screening to a period of 2 years until discontinuation of treatment. Females of childbearing potential are defined as premenopausal and not surgically sterilized, or post-menopausal for fewer than 2 years. A urine pregnancy test will be performed prior to the administration of the study product to confirm negative results. If the urine pregnancy test is positive, the study product will not be administered, and the result will be confirmed by a serum pregnancy test. Urine pregnancy tests will be performed by qualified personnel using kit. Persons becoming pregnant during the study will continue to be monitored for the duration of the study or completion of the pregnancy, whichever is longer. Monitoring will include perinatal and neonatal outcome. Any Serious Adverse Events (SAE) associated with pregnancy will be recorded. - All skin phototypes = grade I of Fitzpatrick's classification. - Mild-to-moderate global face wrinkles and mild-to-moderate global fine lines based on a modified Griffiths' 10-point scale [3]. - Fully understanding of the requirements of the study and willingness to comply with the treatment plan, including laboratory tests, diagnostic imaging, and follow-up visits and assessments. - Volunteer willingness to discontinue any other anti-aging topical or parenteral treatments for the duration of the study. - Can provide written informed consent and complete HIPAA documentation after the nature of the study is fully explained and prior to any study-related treatment. - Can provide written informed consent to being photographed for purposes of treatment for medical, scientific purposes. Exclusion Criteria: - Pregnant or nursing, or planning on becoming pregnant during the study period - Subjects who have had an antiaging or aesthetic treatment prior to the study: Botox or Botox-like products, peelings, plastic surgery, resurfacing with Laser, Intense pulsed light (IPL) therapy, threats, radiofrequency treatments, hyaluronic acid treatment, Plasma-Rich Platelets treatment, or any other specific treatments prone to change the skin aspect during the last 6 months - Individuals with a history of any dermatological disease or condition, including but not limited to active atopic dermatitis, psoriasis, eczema, active seasonal allergies, collagen diseases, or skin cancer involving the treated sites within the past 6 months - Cutaneous marks on the experimental area which could interfere with the assessment of skin reactions (pigmentation problems, scar elements, over-developed pilosity, ephelides, and nevi in too great quantity, sunburn, beauty spots, freckles, etc.) - Participants with asymmetric photodamage on dorsal hands due to environmental exposures (i.e., golfing) and/or other skin lesions including burns or scars resulting in significant skin surface variability between dorsal hands - Eczematous reaction still visible, scar, or pigmentary sequelae of previous tests on the experimental area - Allergy to colophony or nickel. - Allergy or reactivity to drugs, food or cosmetic products previously observed, including perfumes or cologne products. - Skin hyper-reactivity. - Forecast of intensive sun, tanning bed use or UV phototherapy during the test period. - Treatment with prescription-strength Vitamin A acid or its derivatives within 3 months before the beginning of the study. - Treatment with topical steroids on the experimental area within 16 days before the study. Study constraints: - No application of products on the experimental area (except the suggested ones), particularly any anti-aging cosmetic products except for sunscreen. - No change in hygiene habits - No application of any cosmetic moisturizing products on the face or any makeup on face and lips, on the day of study evaluations - No change in the way of life or in the physical activity - No change in dietary activities, or any treatment that significantly impacts body weight - No exfoliating treatment on the experimental areas - Description of any treatment undertaken during the study and all eventual deviations |
Country | Name | City | State |
---|---|---|---|
United States | Mayo Clinic | Rochester | Minnesota |
Lead Sponsor | Collaborator |
---|---|
Mayo Clinic |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in redness area | Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS using RBX technology to measure redness pixel variation and the cross polarized image will be transformed into red images that correlated with hemoglobin absorption/distribution. | baseline, 6, 12, 26,52 weeks | |
Primary | Change brown spot area | Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it, producing a score from 0 to 1, where 0 is less melanin or brown color and 1 is more melanin or brown color. Lower scores reflect better outcomes. | baseline, 6, 12, 26,52 weeks | |
Primary | Change in luminosity | Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it, producing a score from 0 to 1, where 0 is dull and/or uneven skin tone and 1 is radiant and/or even-appearing skin tone. Higher scores reflect better outcomes. | baseline, 6, 12, 26,52 weeks | |
Primary | Change in color evenness | Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess overall variation in color values specifically pixel variation across defined cosmetic subunits and how rapidly those colors change spatially within it, producing a score from 0 to 1, where 0 is dull and/or uneven skin tone and 1 is radiant and/or even-appearing skin tone. Higher scores reflect better outcomes. | baseline, 6, 12, 26,52 weeks | |
Primary | Change in wrinkles area | Photodocumentation with the VISIA-CR Generation 5 3D PRIMOS to assess wrinkles using 3D fringe projection which evaluates static wrinkles and measures the difference in fractional area change | baseline, 6, 12, 26,52 weeks | |
Secondary | Cosmetic skin improvement | Change measured by the self reported Global Aesthetic Improvement Assessment where subjects grade/rate their improvement as Exceptional/very much improved, Moderate/much improved, Slight, No change or Worse. | baseline, 6, 12, 26,52 weeks | |
Secondary | Satisfaction with topical cosmetic treatment | Number of subjects to self report satisfied or very satisfied with the treatment on the Modified Cosmetic Improvement questionnaire. | 52 weeks | |
Secondary | Recommendation of topical cosmetic treatment | Number of subjects to self report they would recommend the treatment to a friend on the Modified Cosmetic Improvement questionnaire. | 52 weeks | |
Secondary | Likelihood of continuing topical cosmetic treatment | Number of subjects to self report they are very likely to continue treatment on the Modified Cosmetic Improvement questionnaire. | 52 weeks | |
Secondary | Topical cosmetic treatment on self-esteem | Number of subjects to self report how the cosmetic treatment affected self-esteem positively or negatively on the Modified Cosmetic Improvement questionnaire. | 52 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04276753 -
A Randomized, Double-blinded, Placebo Controlled, Monocentric Study to Evaluate the Anti-ageing and Skin Brightening Benefit of the Test Product in Healthy Female Subjects
|
N/A | |
Completed |
NCT06125912 -
A Comparative Split-Face Study of the Effects of a Retinol Alternative Cream on Improving Facial Skin Aging
|
N/A | |
Completed |
NCT02580370 -
Safety and Efficacy of Botulinum Toxin Type A Topical Gel for Lateral Canthal Lines
|
Phase 3 | |
Recruiting |
NCT01583478 -
Comparison of Escalating Doses of IncobotulinumtoxinA (Xeomin®) in the Treatment of Glabellar Rhytids
|
Phase 4 | |
Completed |
NCT02003833 -
Poly-L-lactic Acid for Skin Quality
|
Phase 4 | |
Completed |
NCT01447342 -
A Study to Evaluate the Safety and Effectiveness of the Cryo-Touch II Device for the Treatment of Forehead and/or Glabellar Lines
|
Phase 2/Phase 3 | |
Completed |
NCT00986570 -
Clinical Trial to Assess Efficacy, Safety and Tolerability of Botulinum Toxin A (Xeomin®) in Treatment of Expression Wrinkles in the Upper Third of the Face
|
Phase 3 | |
Completed |
NCT00974480 -
Comparison of Redermic, Rejuva-A and Combination of Both Redermic and Rejuva-A in Subjects With Signs of Aging
|
N/A | |
Completed |
NCT00272610 -
Topical Vitamin A Versus Vehicle Cream in the Treatment of Aged Skin
|
Phase 2 | |
Recruiting |
NCT03730649 -
Effect of Topical Sulforaphane on Skin Aging and With Ultraviolet and Visible Light Exposure
|
Early Phase 1 | |
Completed |
NCT03312543 -
Evaluation of the Efficacy and Tolerance of a Light Therapy Mask on Mild to Moderate Brown Spots and Moderate to Severe Facial Wrinkles
|
N/A | |
Active, not recruiting |
NCT05349799 -
TEOSYAL RHA® 1 for Neck Lines, Perioral Lines and Smiling Lines
|
N/A | |
Completed |
NCT03677258 -
Effectiveness and Safety of Collagen Complex COLLOST in Anti-age Therapy
|
N/A | |
Withdrawn |
NCT05854628 -
The Role of Red Flavonoid in Photoaging
|
N/A | |
Completed |
NCT01981980 -
Comparison of the Effects of Carboxytherapy and Radiofrequency on Skin Rejuvenation
|
N/A | |
Not yet recruiting |
NCT00767156 -
Effects of Oral and Topical Sea Buckthorn Oil Treatments on Skin Aging
|
N/A | |
Recruiting |
NCT05813054 -
Clinical Study to Evaluate the Anti-aging Efficacy of Dermial®
|
N/A | |
Not yet recruiting |
NCT04485091 -
TCA Peel and Photobiomodulation for Hand Rejuvenation
|
Phase 2 | |
Completed |
NCT01237977 -
Efficacy and Safety Study of Botulinum Toxin Type A to Treat Glabellar Lines
|
Phase 3 | |
Completed |
NCT01029301 -
Evaluation of Safety and Efficacy of Using EndyMed Pro Skin Treatment System for Skin Wrinkle Treatment on Body Areas
|
N/A |